Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Capecitabine in HER2-positive Metastatic Breast Cancer
NCT01290718Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2011
- Primary completion
- Dec 2012
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, capecitabine in HER2-positive breast cancer, sponsored by Roche. Started Dec 2011; status: terminated.
02
Drugs
trastuzumabcapecitabine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01290718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290718.